Pancreatic Cancer Research

Clinical trialPhase 1Recruiting

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Outcome
Ongoing
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Start
13 November 2025
Expected end
31 March 2030
Enrollment
76 participants
Sites
7
Primary outcomes
Part A (Dose Finding): To determine the Maximum Tolerated Dose (MTD); Number of participants with treatment related adverse events as assessed by CTCAE version 5.0; To evaluate safety and tolerability of KIVU-107
Sponsor type
Industry
Results posted
No
Last update
24 September 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.

Detailed description public domain (ClinicalTrials.gov)

Part A: The primary objective of Part A of this study is to evaluate the safety and tolerability of KIVU-107 and to determine the maximum tolerated dose (MTD)/Recommended Dose for Expansion (RDE). Part B: The primary objective of Part B of this study is to confirm the safety and tolerability of KIVU-107 at the RDE.